About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Splenomegaly in Polycythemia Vera: Clinical Significance and Relation to Myelofibrosis and Survival
By
Richard T. Silver
2 Videos
0 views
December 16, 2021
Comments
0
Login to view comments.
Click here to Login
Featured Video
11:12
Stemline
A proven CD123 targeted therapy for BPDCN
Feat.
H. Erba
Featured Video
01:29
Incyte
Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD
Recommended
AUTOPLAY
ON
Related
Newest
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
22:37
Insights from 2023 ASH Annual Meeting
AML and MDS Highlights & Key Takeaways
Feat.
T. Badar
31:53
Indy Hematology Review
HSCT in 2024: What Every Hematologist Needs to Know
Feat.
R. Childs
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
08:18
Insights from 2023 ASH Annual Meeting
Treatment Strategies for Hematocrit Control in PV
Feat.
A. Zhou
16:18
Masterclasses in Dermatology
Masterclasses from the Wards
Feat.
S. Elman
23:35
University of Colorado Division of Hematology
2024 Updates in PV/ET
Feat.
B. McMahon
24:27
BMFcases
Experts Discuss Pros and Cons of Treatment Approaches in PV
Feat.
T. Bat,
A. Tefferi
27:49
Insights from 2024 EHA Annual Meeting
AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024
Feat.
T. Badar
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
18:04
Ruben Mesa
Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…
17:05
BMFcases
Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…
Feat.
T. Bat,
A. Tefferi
16:55
Moffitt Cancer Center
Making Sense of the New Classification Systems for MDS in 2024
Feat.
R. Komrokji
06:18
Cleveland Clinic Taussig Cancer Institute
SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…
Feat.
A. Gerds
09:42
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based Gv…
Feat.
M. Al Malki
12:36
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…
Feat.
A. Patel
12:15
Moffitt Cancer Center
Using Transplant in Patients With p53 Mutant MDS or AML
Feat.
H. Elmariah
32:04
Moffitt Cancer Center
Experts Discuss the Latest Data in Myeloid Diseases
Feat.
A. Kuykendall,
R. Komrokji,
O. Chan,
D. Sallman
